(Reuters) - The French drugmaker said it would work towards resubmitting the medicine, known by the brand names Acomplia and Zimulti, at a future date and would undertake necessary talks with the Food and Drug Administration on required modifications to its file.
Read more at Reuters.com Government Filings News
Read more at Reuters.com Government Filings News
1 comment:
Hello there...
Nice blog and have a nice day
^^^infodepot^^^
menarique
You are always invited to my place!!
Post a Comment